Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110222 | 1.00 | GAA (0.39) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL17118117 | 0.84 | MEN1 (0.44) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL2074992 | 0.78 | GAA (0.51) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL23038833 | 0.74 | MEN1 (0.45) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL25978289 | 0.74 | MEN1 (0.45) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL25978287 | 0.74 | MEN1 (0.45) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL2329093 | 0.73 | MEN1 (0.44) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL15600327 | 0.73 | GAA (0.44) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL9638826 | 0.72 | GAA (0.46) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL20046896 | 0.72 | GAA (0.46) | GAAMEN1MAPK1KMT2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | GAA 3413/4885MEN1 4091/4885MAPK1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.